Immune thrombocytopenia: epidemiological and clinical features of 216 patients in northwestern Turkey

Basit Öğe Kaydı
dc.authorwosidUyanik, Mehmet/AAD-7345-2020
dc.contributor.authorKoylu, Ahmet
dc.contributor.authorPamuk, Gulsum Emel
dc.contributor.authorUyanik, Mehmet Sevki
dc.contributor.authorDemir, Muzaffer
dc.contributor.authorPamuk, Omer Nuri
dc.date.accessioned2024-06-12T11:03:41Z
dc.date.available2024-06-12T11:03:41Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractWe evaluated the clinical features, treatment modalities, treatment responses, and prognosis of our patients with immune thrombocytopenia (ITP). Furthermore, we estimated the frequency of ITP in the Thrace region of Turkey. Two hundred sixteen patients diagnosed with ITP between 2000 and 2012 at our center were retrospectively evaluated. Patients' clinical features, treatments, and responses to treatment modalities were recorded. The mean annual incidence of ITP was 2.92/100,000 (95%CI: 1.57-4.27). The overall prevalence of ITP was 35.1/100,000 (95%CI: 30.3-39.8). The administration of first-line therapy resulted in complete remission (CR) in 76.5 % of patients and partial remission (PR) in 13.6 %. After 5 years, 33 % of patients who were responsive to first-line therapy were still in relapse-free remission. Of patients who were given second-line therapy, CR was obtained in 71.3 % and PR in 14.9 %. The duration of relapse-free remission was longer with splenectomy than with steroids (p < 0.001). Five years after splenectomy, 62 % of patients were in relapse-free remission; contrarily, this was lower with steroids (36 % at 5 years). The annual incidence and prevalence of ITP in northwestern Turkey was similar to data from western countries-at the lower limit for some countries. Effective treatment strategies seem to be steroids as first-line therapy and splenectomy in refractory cases.en_US
dc.identifier.doi10.1007/s00277-014-2220-z
dc.identifier.endpage466en_US
dc.identifier.issn0939-5555
dc.identifier.issn1432-0584
dc.identifier.issue3en_US
dc.identifier.pmid25238800en_US
dc.identifier.scopus2-s2.0-84925497015en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage459en_US
dc.identifier.urihttps://doi.org/10.1007/s00277-014-2220-z
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21757
dc.identifier.volume94en_US
dc.identifier.wosWOS:000349225200013en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofAnnals Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmune Thrombocytopenia (ITP)en_US
dc.subjectIncidenceen_US
dc.subjectPrevalenceen_US
dc.subjectCorticosteroidsen_US
dc.subjectSplenectomyen_US
dc.subjectPurpuraen_US
dc.subjectManagementen_US
dc.subjectItpen_US
dc.subjectSplenectomyen_US
dc.subjectChildrenen_US
dc.subjectAdultsen_US
dc.subjectPathogenesisen_US
dc.subjectDefinitionsen_US
dc.subjectTerminologyen_US
dc.subjectEltrombopagen_US
dc.titleImmune thrombocytopenia: epidemiological and clinical features of 216 patients in northwestern Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu